

# Press release

Lund, 13 January, 2025  
EQL Pharma AB (publ)  
556713-3425

EQL PHARMA

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR TO ANY PERSON LOCATED OR RESIDENT IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES TO DISTRIBUTE THIS ANNOUNCEMENT.

## EQL Pharma AB (publ) contemplates to issue senior secured bonds and publishes preliminary figures as of 31 December 2024

As announced on 10 December 2024, EQL Pharma AB (publ) (the “**Company**” or “**EQL**”) has signed an asset purchase agreement in respect of the acquisition of a portfolio with original pharmaceuticals (the “**Acquisition**”). Completion of the Acquisition is subject to, among other things, a financing condition.

EQL has mandated ABG Sundal Collier AB as sole bookrunner to arrange fixed income investor meetings from and including 14 January 2025 to investigate the possibility to issue senior secured floating rate bonds with an expected issue amount of SEK 350 million under a total framework amount of SEK 700 million. A capital market transaction may follow, subject to prevailing market conditions.

In connection with the fixed income meetings, EQL has also published a company presentation (the “**Company Presentation**”) which includes information regarding the Acquisition and preliminary figures for the Company’s third financial quarter (ending on 31 December 2024). Net sales and adj. EBITDA for the last twelve months amounted to SEK 338 million and SEK 66 million, respectively. Further information can be found in the Company Presentation which is available on the following link: <https://investor.eqlpharma.com/en/reports/interim-reports/>.

Advokatfirman Vinge acts as legal advisor.

This disclosure contains information that EQL Pharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact persons, on 2025-01-13 08:00 CET.

**For further information, please contact:**

**Axel Schörling**

**CEO, EQL Pharma AB (publ)**

**Phone: +46 (0) 76 317 90 60**

**E-mail: [axel.schorling@eqlpharma.com](mailto:axel.schorling@eqlpharma.com)**

**Website: [www.eqlpharma.com](http://www.eqlpharma.com)**

**EQL Pharma AB (publ) briefly**

EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has more than 40 niche generics (i.e., generics with limited competition apart from the original drug) launched in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2024 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, in the Nordics and selected European markets. EQL Pharma AB has its operations in Lund and is listed on Nasdaq Stockholm. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.